TheraRadar
Clinical-Stage Companies / Shanghai Ark Biopharmaceutical

Shanghai Ark Biopharmaceutical

Pre-Approval PRO BETA
19
Total Trials
5
Phase 3
5
Phase 2
3
Recruiting
163
Score

Pipeline by Phase

Phase 3
5
Phase 2
5
Phase 1
11

Therapeutic Focus

Respiratory Syncytial Virus Infections Healthy Healthy Participants Healthy Volunteer Study Respiratory Synctial Virus Infections

Clinical Trials (19)

NCT06775405 Phase 3 RECRUITING

A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

Started: 2/29/2024

NCT04231968 Phase 3 COMPLETED

A Study of AK0529 in Chinese Infants Hospitalized With RSV

Started: 9/22/2020

NCT06359899 Phase 3 COMPLETED

A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD

Started: 5/28/2024

NCT07719023 Phase 3 NOT YET RECRUITING

A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

Started: 8/31/2026

NCT07658534 Phase 2 RECRUITING

A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

Started: 3/3/2026

NCT06942299 Phase 2 COMPLETED

A Study of AK0529 in Adults Patients Hospitalized With RSV Infection

Started: 7/20/2023

NCT02654171 Phase 2 COMPLETED

Viral Inhibition in Children for Treatment of RSV

Started: 5/27/2016

NCT03699202 Phase 2 TERMINATED

Anti-RSV Study in Chinese Patients (ASCENT)

Started: 3/28/2019

NCT06996704 Phase 1 RECRUITING

A Clinical Study of AK0610

Started: 2/29/2024

NCT07432698 Phase 1 NOT YET RECRUITING

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants

Started: 2/1/2026

NCT06591845 Phase 1 COMPLETED

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

Started: 9/25/2024

NCT04926116 Phase 1 COMPLETED

A Study of AK3280 in Chinese Healthy Volunteers

Started: 6/9/2021

NCT04788017 Phase 1 COMPLETED

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Started: 3/24/2021

NCT03322800 Phase 1 COMPLETED

A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers

Started: 10/23/2017

NCT03990688 Phase 1 COMPLETED

A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects

Started: 10/3/2019

NCT03400995 Phase 1 COMPLETED

A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

Started: 1/5/2018

NCT02460016 Phase 1 TERMINATED

A Study of AK0529 in Infants Hospitalized With RSV

Started: 8/28/2015

NCT02297594 Phase 1 COMPLETED

Safety, Tolerability and PK Study of AK0529 in Healthy Human

Started: 10/1/2014

NCT05434897 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar

Started: 7/8/2022

Drug Candidates

AK0406 150 mg AK0406 300 mg AK0406 600 mg AK0406 900 mg AK0610 Injection solution AK0529 Ziresovir 125 mg Ziresovir 500 mg AK3280 Ziresovir
Activity Status: Active
Last Trial Started: 8/31/2026
Last Trial Ended: 1/11/2025
Trials (12 months): 3
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.